NBIX RSI Chart
Last 7 days
4.1%
Last 30 days
3.1%
Last 90 days
5.1%
Trailing 12 Months
46.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 2.0B | 0 | 0 | 0 |
2023 | 1.6B | 1.7B | 1.8B | 1.9B |
2022 | 1.2B | 1.3B | 1.4B | 1.5B |
2021 | 1.0B | 1.0B | 1.1B | 1.1B |
2020 | 886.8M | 1.0B | 1.0B | 1.0B |
2019 | 518.6M | 605.1M | 675.5M | 788.1M |
2018 | 232.7M | 323.3M | 414.3M | 451.2M |
2017 | 0 | 6.3M | 67.1M | 161.6M |
2016 | 15.0M | 15.0M | 15.0M | 15.0M |
2015 | 22.0M | 21.2M | 20.5M | 19.8M |
2013 | 40.6M | 28.0M | 15.5M | 2.9M |
2012 | 76.2M | 74.6M | 42.3M | 53.1M |
2011 | 45.3M | 52.8M | 80.0M | 77.4M |
2010 | 0 | 13.1M | 23.3M | 33.5M |
2009 | 0 | 0 | 0 | 3.0M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 15, 2024 | benevich eric | sold | -2,643,020 | 133 | -19,818 | chief commercial officer |
Apr 15, 2024 | benevich eric | acquired | 1,609,430 | 81.2105 | 19,818 | chief commercial officer |
Apr 01, 2024 | delaet ingrid | sold | -37,345 | 137 | -272 | chief regulatory officer |
Apr 01, 2024 | delaet ingrid | acquired | 21,493 | 79.02 | 272 | chief regulatory officer |
Mar 21, 2024 | delaet ingrid | acquired | 517,600 | 103 | 5,000 | chief regulatory officer |
Mar 21, 2024 | delaet ingrid | sold | -725,320 | 145 | -5,000 | chief regulatory officer |
Mar 14, 2024 | morrow george j | sold | -5,576,710 | 139 | -40,000 | - |
Mar 14, 2024 | morrow george j | acquired | 795,800 | 39.79 | 20,000 | - |
Mar 14, 2024 | benevich eric | sold | -10,453,400 | 139 | -75,000 | chief commercial officer |
Mar 14, 2024 | benevich eric | acquired | 6,067,630 | 80.9017 | 75,000 | chief commercial officer |
Which funds bought or sold NBIX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | DiNuzzo Private Wealth, Inc. | unchanged | - | 31.00 | 690 | -% |
May 06, 2024 | Advisory Services Network, LLC | sold off | -100 | -1,055 | - | -% |
May 06, 2024 | LMCG INVESTMENTS, LLC | reduced | -27.85 | -303,970 | 938,132 | 0.06% |
May 06, 2024 | TEACHER RETIREMENT SYSTEM OF TEXAS | reduced | -2.18 | 72,000 | 3,081,000 | 0.02% |
May 06, 2024 | Quantbot Technologies LP | reduced | -98.46 | -219,220 | 3,586 | -% |
May 06, 2024 | HighTower Advisors, LLC | added | 3.61 | 185,000 | 2,212,000 | -% |
May 06, 2024 | NEW YORK LIFE INVESTMENT MANAGEMENT LLC | reduced | -2.4 | 31,925 | 1,505,400 | 0.01% |
May 06, 2024 | Savant Capital, LLC | new | - | 2,150,590 | 2,150,590 | 0.03% |
May 06, 2024 | Manchester Capital Management LLC | new | - | 414 | 414 | -% |
May 06, 2024 | Envestnet Portfolio Solutions, Inc. | added | 0.47 | 17,240 | 350,593 | -% |
Unveiling Neurocrine Biosciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Neurocrine Biosciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 357.8B | 85.6B | 9.3 | 4.18 | ||||
MRK | 330.2B | 61.4B | 143.19 | 5.38 | ||||
AMGN | 161.1B | 29.5B | 42.82 | 5.46 | ||||
PFE | 156.8B | 46.5B | -112.94 | 3.37 | ||||
GILD | 81.5B | 27.1B | 14.39 | 3.01 | ||||
TEVA | 15.6B | 15.8B | -27.14 | 0.99 | ||||
MID-CAP | ||||||||
ALKS | 4.2B | 1.7B | 9.58 | 2.41 | ||||
PRGO | 4.1B | 4.6B | -533.77 | 0.9 | ||||
BHC | 2.7B | 9.0B | -5.97 | 0.3 | ||||
AMPH | 2.1B | 644.4M | 14.96 | 3.19 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.38 | 2.07 | ||||
TXMD | 23.2M | 1.3M | -2.26 | 17.8 | ||||
ACRX | 17.0M | - | -0.92 | 0.22 | ||||
AGRX | 2.7M | 19.6M | -0.19 | 0.14 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
Neurocrine Biosciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 0.0% | 515 | 515 | 499 | 453 | 420 | 412 | 388 | 378 | 311 | 312 | 296 | 289 | 237 | 248 | 259 | 302 | 237 | 244 | 222 | 184 | 138 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00 | 2.00 | 2.00 | - | 1.00 |
Costs and Expenses | 14.0% | 416 | 365 | 358 | 379 | 535 | 309 | 300 | 324 | 308 | 348 | 252 | 226 | 205 | 176 | 303 | 226 | 178 | - | 132 | 149 | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | 326 | - | - | - | 176 | 303 | 226 | 178 | 195 | 132 | 149 | 239 |
S&GA Expenses | 11.1% | 243 | 219 | 204 | 222 | 243 | 183 | 186 | 183 | 201 | 157 | 155 | 143 | 129 | 107 | 113 | 97.00 | 118 | 101 | 85.00 | 81.00 | 88.00 |
R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 73.00 | - | - | - | 58.00 | - | - | 62.00 | 38.00 |
EBITDA Margin | 32.2% | 0.25* | 0.19* | 0.15* | 0.15* | 0.07* | 0.16* | 0.08* | 0.04* | 0.11* | 0.12* | 0.18* | 0.10* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 3.00 | 7.00 | 7.00 | 6.00 | 6.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 |
Income Taxes | -117.6% | -8.90 | 51.00 | 33.00 | 26.00 | -26.70 | 29.00 | 29.00 | -6.40 | 8.00 | -6.50 | 8.00 | 15.00 | -4.90 | -306 | 1.00 | 4.00 | 2.00 | 5.00 | 5.00 | 1.00 | -0.50 |
Earnings Before Taxes | -82.6% | 35.00 | 198 | 116 | 122 | -103 | 118 | 98.00 | -23.30 | 21.00 | -13.80 | 31.00 | 58.00 | 27.00 | 42.00 | -57.10 | 83.00 | 39.00 | 39.00 | 58.00 | 52.00 | -102 |
EBT Margin | 34.7% | 0.24* | 0.18* | 0.14* | 0.14* | 0.06* | 0.14* | 0.06* | 0.01* | 0.08* | 0.09* | 0.15* | 0.07* | - | - | - | - | - | - | - | - | - |
Net Income | -70.6% | 43.00 | 148 | 83.00 | 96.00 | -76.60 | 89.00 | 69.00 | -16.90 | 14.00 | -7.30 | 23.00 | 42.00 | 32.00 | 348 | -57.60 | 80.00 | 37.00 | 34.00 | 54.00 | 51.00 | -102 |
Net Income Margin | 41.0% | 0.19* | 0.13* | 0.11* | 0.11* | 0.04* | 0.10* | 0.04* | 0.01* | 0.06* | 0.08* | 0.42* | 0.35* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 0.8% | 119 | 118 | 204 | 173 | -133 | 141 | 101 | 129 | -48.10 | -4.70 | 56.00 | 99.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 6.8% | 3,472 | 3,251 | 2,848 | 2,613 | 2,360 | 2,369 | 2,143 | 2,006 | 2,145 | 2,073 | 2,017 | 1,956 | 1,846 | 1,735 | 1,503 | 1,516 | 1,362 | 1,306 | 1,180 | 1,067 | 958 |
Current Assets | 11.9% | 1,799 | 1,607 | 1,650 | 1,497 | 1,433 | 1,454 | 1,206 | 1,019 | 1,018 | 973 | 1,006 | 1,110 | 1,085 | 1,016 | 1,157 | 1,146 | 968 | 831 | 819 | 749 | 633 |
Cash Equivalents | 61.0% | 404 | 251 | 294 | 160 | 104 | 263 | 212 | 163 | 270 | 344 | 311 | 368 | 353 | 190 | 425 | 415 | 187 | 116 | 172 | 147 | 78.00 |
Inventory | -2.9% | 37.00 | 38.00 | 29.00 | 32.00 | 33.00 | 35.00 | 37.00 | 29.00 | 29.00 | 31.00 | 26.00 | 28.00 | 30.00 | 28.00 | 21.00 | 22.00 | 21.00 | 17.00 | 11.00 | 12.00 | 13.00 |
Net PPE | 6.4% | 75.00 | 71.00 | 69.00 | 66.00 | 63.00 | 59.00 | 61.00 | 67.00 | 64.00 | 59.00 | 51.00 | 50.00 | 45.00 | 45.00 | 43.00 | 45.00 | 42.00 | 42.00 | 40.00 | 40.00 | 37.00 |
Liabilities | 6.6% | 1,086 | 1,019 | 846 | 760 | 675 | 661 | 599 | 582 | 753 | 699 | 671 | 677 | 641 | 609 | 698 | 684 | 662 | 669 | 605 | 583 | 548 |
Current Liabilities | 8.9% | 713 | 655 | 692 | 583 | 374 | 538 | 485 | 286 | 254 | 246 | 226 | 213 | 190 | 187 | 611 | 573 | 140 | 565 | 116 | 101 | 72.00 |
Long Term Debt | - | - | - | - | - | 170 | - | - | 169 | 378 | 335 | 331 | 326 | 322 | 318 | - | - | 414 | - | 404 | 398 | 393 |
LT Debt, Current | -27.8% | 123 | 170 | 170 | 170 | - | 169 | 169 | - | - | - | - | - | - | - | 425 | 420 | - | 409 | - | - | - |
LT Debt, Non Current | - | - | - | - | - | 170 | - | - | 169 | 378 | 335 | 331 | 326 | 322 | 318 | - | - | 414 | - | 404 | 398 | 393 |
Shareholder's Equity | 6.9% | 2,386 | 2,232 | 2,002 | 1,853 | 1,685 | 1,708 | 1,545 | 1,423 | 1,391 | 1,374 | 1,346 | 1,279 | 1,206 | 1,126 | 804 | 831 | 700 | 637 | 575 | 484 | 409 |
Retained Earnings | 27.6% | -113 | -157 | -304 | -387 | -483 | -406 | -495 | -564 | -547 | -635 | -628 | -651 | -693 | -725 | -1,073 | -1,015 | -1,095 | -1,132 | -1,166 | -1,220 | -1,271 |
Additional Paid-In Capital | 4.8% | 2,496 | 2,382 | 2,309 | 2,242 | 2,171 | 2,122 | 2,054 | 2,000 | 1,948 | 2,011 | 1,974 | 1,929 | 1,898 | 1,850 | 1,874 | 1,842 | 1,797 | 1,768 | 1,740 | 1,703 | 1,681 |
Shares Outstanding | 1.9% | 101 | 99.00 | 98.00 | 98.00 | 98.00 | 97.00 | 96.00 | 95.00 | 95.00 | 95.00 | 95.00 | 94.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 7,900 | - | - | - | 8,097 | - | - | - | 9,105 | - | - | - | 11,232 | - | - | - | 5,753 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 5.5% | 130,300 | 123,500 | 212,000 | 179,600 | -125,200 | 143,000 | 98,800 | 138,100 | -40,500 | 4,200 | 61,800 | 103,200 | 87,300 | 94,500 | -20,400 | 118,900 | 35,500 | 97,500 | 97,800 | 64,200 | -112,500 |
Share Based Compensation | 16.8% | 44,500 | 38,100 | 47,800 | 68,500 | 39,900 | 43,500 | 43,100 | 49,500 | 37,000 | 35,600 | 37,100 | 28,600 | 32,900 | 21,000 | 26,700 | 29,500 | 22,800 | 21,300 | 20,300 | 17,900 | 15,800 |
Cashflow From Investing | 72.7% | -55,000 | -201,800 | -97,300 | -125,900 | -42,100 | -115,600 | -61,300 | 31,400 | -31,600 | 23,700 | -126,200 | -90,800 | 63,100 | -147,700 | 25,200 | 93,400 | 33,200 | -166,200 | -85,600 | -300 | 41,000 |
Cashflow From Financing | 97.5% | 69,900 | 35,400 | 18,800 | 2,900 | 8,200 | 24,600 | 11,400 | -276,400 | 6,100 | 1,800 | 7,500 | 3,000 | 15,100 | -185,000 | 5,400 | 15,800 | 6,000 | 12,400 | 13,100 | 4,300 | 2,600 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Total revenues | $ 515.3 | $ 420.4 |
Operating expenses: | ||
Cost of revenues | 7.5 | 8.5 |
Research and development | 159.4 | 139.5 |
Acquired in-process research and development | 6.0 | 143.9 |
Selling, general and administrative | 243.1 | 242.7 |
Total operating expenses | 416.0 | 534.6 |
Operating income (loss) | 99.3 | (114.2) |
Other (expense) income: | ||
Interest expense | (1.1) | (1.1) |
Unrealized gain on equity security investments | 1.6 | 2.2 |
Charges associated with convertible senior notes | (88.7) | 0.0 |
Investment income and other, net | 23.4 | 9.8 |
Total other (expense) income, net | (64.8) | 10.9 |
Income (loss) before benefit from income taxes | 34.5 | (103.3) |
Benefit from income taxes | (8.9) | (26.7) |
Net income (loss) | 43.4 | (76.6) |
Foreign currency translation adjustments, net of tax | (0.5) | 1.2 |
Unrealized (loss) gain on debt securities available-for-sale, net of tax | (3.2) | 4.0 |
Comprehensive income (loss) | $ 39.7 | $ (71.4) |
Earnings (loss) per share: | ||
Basic (in USD per share) | $ 0.43 | $ (0.79) |
Diluted (in USD per share) | $ 0.42 | $ (0.79) |
Weighted-average shares outstanding: | ||
Basic (in shares) | 99.8 | 97.1 |
Diluted (in shares) | 103.6 | 97.1 |
Net product sales | ||
Revenues: | ||
Total revenues | $ 509.0 | $ 415.3 |
Collaboration revenues | ||
Revenues: | ||
Total revenues | $ 6.3 | $ 5.1 |
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 396.3 | $ 251.1 |
Debt securities available-for-sale | 814.3 | 780.5 |
Accounts receivable | 450.7 | 439.3 |
Inventory | 37.2 | 38.3 |
Other current assets | 100.5 | 97.8 |
Total current assets | 1,799.0 | 1,607.0 |
Deferred tax assets | 378.2 | 362.6 |
Debt securities available-for-sale | 700.4 | 687.5 |
Right-of-use assets | 270.8 | 276.5 |
Equity security investments | 163.5 | 161.9 |
Property and equipment, net | 75.3 | 70.8 |
Intangible assets, net | 34.3 | 35.5 |
Other noncurrent assets | 50.9 | 49.6 |
Total assets | 3,472.4 | 3,251.4 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 417.2 | 448.8 |
Convertible senior notes, at carrying value ($170.4 face value as of March 31, 2024 and December 31, 2023) | 122.8 | 170.1 |
Convertible senior notes embedded derivative liability | 136.2 | 0.0 |
Other current liabilities | 36.7 | 35.9 |
Total current liabilities | 712.9 | 654.8 |
Noncurrent operating lease liabilities | 252.9 | 258.3 |
Other noncurrent liabilities | 120.5 | 106.3 |
Total liabilities | 1,086.3 | 1,019.4 |
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding | 0.0 | 0.0 |
Common stock, $0.001 par value; 220.0 shares authorized; 100.6 and 98.7 shares issued and outstanding, respectively | 0.1 | 0.1 |
Additional paid-in capital | 2,496.4 | 2,382.0 |
Accumulated other comprehensive income | 3.3 | 7.0 |
Accumulated deficit | (113.7) | (157.1) |
Total stockholders’ equity | 2,386.1 | 2,232.0 |
Total liabilities and stockholders’ equity | $ 3,472.4 | $ 3,251.4 |
 | Dr. Kevin C. Gorman Ph.D. |
---|---|
 | neurocrine.com |
 | Pharmaceuticals |
 | 1350 |